Allena Pharmaceuticals (ALNAQ)
OTHER OTC:ALNAQ
US Market
Holding ALNAQ?
Track your performance easily

Allena Pharmaceuticals (ALNAQ) Stock Price & Analysis

1,538 Followers

ALNAQ Stock Chart & Stats


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Website Traffic

Sorry, No Data Available
There is no website visitor data available for this stock.
---

ALNAQ FAQ

What was Allena Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Allena Pharmaceuticals’s market cap?
Currently, no data Available
When is Allena Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Allena Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Allena Pharmaceuticals overvalued?
According to Wall Street analysts Allena Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
    Does Allena Pharmaceuticals pay dividends?
    Allena Pharmaceuticals does not currently pay dividends.
    What is Allena Pharmaceuticals’s EPS estimate?
    Allena Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Allena Pharmaceuticals have?
    Currently, no data Available
    What happened to Allena Pharmaceuticals’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Allena Pharmaceuticals?
    Currently, no hedge funds are holding shares in ALNAQ
    ---

    Allena Pharmaceuticals Stock Smart Score

    10
    Unlock Smart Score
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10

    Company Description

    Allena Pharmaceuticals

    Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes Reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.
    ---
    Similar Stocks
    Company
    Price & Change
    Follow
    Alimera
    Aileron Therapeutics
    Alnylam Pharma
    Alkermes
    Popular Stocks
    ---
    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis